A Selective Inhibitor of Cardiac Troponin I Phosphorylation by Delta Protein Kinase C (δPKC) as a Treatment for...

Area of Science:

• Cardiovascular Science
• Biochemistry
• Pharmacology

Background:

• Myocardial infarction (MI) is a primary cause of cardiovascular mortality.
• Myocardial injury during ischemia-reperfusion (IR) is a significant contributor to MI outcomes.
• Protein kinase C delta (PKCδ) plays a role in IR-induced myocardial injury.

Purpose of the Study:

• To investigate a novel peptide inhibitor targeting the interaction between cardiac troponin I (cTnI) and PKCδ.
• To evaluate the efficacy of this peptide in preventing myocardial injury and mitochondrial dysfunction in an ex vivo model of MI.
• To explore a new therapeutic target for reducing cardiac damage post-MI.

Main Methods:

• Development of a selective peptide inhibitor (ψTnI) targeting cTnI phosphorylation by PKCδ.
• Utilized a Langendorff model for ex vivo myocardial infarction.
• Assessed myocardial tissue injury and mitochondrial function post-treatment with ψTnI.

Main Results:

• The ψTnI peptide successfully inhibited cTnI interaction with and phosphorylation by PKCδ.
• ψTnI treatment prevented myocardial tissue injury in the ex vivo MI model.
• Unexpectedly, ψTnI also attenuated IR-induced mitochondrial dysfunction.

Conclusions:

• PKCδ-mediated phosphorylation of cTnI is a critical factor in IR-induced myocardial injury.
• The developed ψTnI peptide demonstrates therapeutic potential for reducing cardiac damage.
• Inhibiting the cTnI/PKCδ interaction represents a promising therapeutic strategy for myocardial infarction.